

<i>Technology appraisal (TA)</i>	<i>Date of TA Release</i>	<i>Adherence of local formulary to NICE</i>	
		<i>Included on the Trust Formulary for this indication Yes OR No</i>	<i>Reason provided if "No"</i>
2017-18			
TA516 - Cabozantinib for treating medullary thyroid cancer	28/03/2018	No	Not applicable to CWFT
TA515 - Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen	28/03/2018	No	Not recommended
TA514 - Regorafenib for previously treated advanced hepatocellular carcinoma	21/03/2018	No	Not recommended
TA513 - Obinutuzumab for untreated advanced follicular lymphoma	21/03/2018	Yes	
TA512 - Tivozanib for treating advanced renal cell carcinoma	21/03/2018	No	Not applicable to CWFT
TA511 - Brodalumab for treating moderate to severe plaque psoriasis	21/03/2018	Yes	
TA510 - Daratumumab monotherapy for treating relapsed and refractory multiple myeloma	14/03/2018	Yes	
TA509 - Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer	07/03/2018	Yes	
TA508 - Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee	07/03/2018	No	Not applicable to CWFT
TA507 - Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C	21/02/2018	Yes	
TA506 - Lesinurad for treating chronic hyperuricaemia in people with gout	07/02/2018	No	Not recommended
TA505 - Ixazomb with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma	07/02/2018	Yes	
TA504 - Pirfenidone for treating idiopathic pulmonary fibrosis	06/02/2018	No	Not applicable to CWFT
TA503 - Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer	31/01/2018	No	Not recommended
TA4502 - Ibrutinib for treating relapsed or refractory mantle cell lymphoma	31/01/2018	Yes	
TA501 - Intrabeam radiotherapy system for adjuvant treatment of early breast cancer	31/01/2018	No	Not applicable to CWFT
TA500 - Ceritinib for untreated ALK-positive non-small-cell lung cancer	24/01/2018	Yes	
TA499 - Glecaprevir–pibrentasvir for treating chronic hepatitis C	24/01/2018	Yes	
TA498 - Lenvatinib with everolimus for previously treated advanced renal cell carcinoma	24/01/2018	Yes	
TA497 - Golimumab for treating non-radiographic axial spondyloarthritis	10/01/2017	Yes	
TA496 - Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer	20/12/2017	Yes	
TA495 - Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer	20/12/2017	Yes	
TA494 - Naltrexone–bupropion for managing overweight and obesity	12/12/2017	No	Not recommended
TA493 - Cladribine tablets for treating relapsing–remitting multiple sclerosis	06/12/2017	No	Not applicable to CWFT
TA492 - Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable	06/12/2017	Yes	
TA491 - Ibrutinib for treating Waldenstrom's macroglobulinaemia	22/11/2017	Yes	
TA490 - Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy	22/11/2017	No	Not applicable to CWFT
TA489 - Vismodegib for treating basal cell carcinoma	22/11/2017	No	Not recommended
TA488 - Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours	15/11/2017	No	Not applicable to CWFT
TA487 - Venetoclax for treating chronic lymphocytic leukaemia	08/11/2017	Yes	
TA486 - Afibercept for treating choroidal neovascularisation	01/11/2017	Yes	
TA485 - Sarilumab for moderate to severe rheumatoid arthritis	01/11/2017	Yes	
TA484 - Nivolumab for previously treated non-squamous non-small-cell lung cancer	01/11/2017	Yes	
TA483 - Nivolumab for previously treated squamous non-small-cell lung cancer	01/11/2017	Yes	
TA482 - Immunosuppressive therapy for kidney transplant in children and young people	11/10/2017	No	Not applicable to CWFT
TA481 - Immunosuppressive therapy for kidney transplant in adults	11/10/2017	No	Not applicable to CWFT
TA480 - Tofacitinib for moderate to severe rheumatoid arthritis	11/10/2017	Yes	

TA479 - Reslizumab for treating severe eosinophilic asthma	04/10/2017	No	Not applicable to CWFT
TA478 - Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma	04/10/2017	Yes	
TA477 - Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee	04/10/2017	N/A	Not drug related
TA476 - Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer	06/09/2017	No	Not applicable to CWFT
TA475 - Dimethyl fumarate for treating moderate to severe plaque psoriasis	06/09/2017	Yes	
TA474 - Sorafenib for treating advanced hepatocellular carcinoma	06/09/2017	No	Not applicable to CWFT
TA473 - Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck	31/08/2017	No	Not applicable to CWFT
TA472 - Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab	30/08/2017	Yes	
TA471 - Eluxadoline for treating irritable bowel syndrome with diarrhoea	30/08/2017	Yes	
TA470 - Ofatumumab with chemotherapy for treating chronic lymphocytic leukaemia	23/08/2017	No	Appraisal terminated
TA469 - Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia	23/08/2017	No	Appraisal terminated
TA468 - Methylnaltrexone bromide for treating opioid-induced constipation	23/08/2017	No	Appraisal terminated
TA467 - Holoclair for treating limbal stem cell deficiency after eye burns	09/08/2017	No	Not applicable to CWFT
TA466 - Baricitinib for moderate to severe rheumatoid arthritis	09/08/2017	Yes	
TA465 - Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma	09/08/2017	No	Not applicable to CWFT
TA464 - Bisphosphonates for treating osteoporosis	09/08/2017	Yes	
TA463 - Cabozantinib for previously treated advanced renal cell carcinoma	09/08/2017	Yes	
TA462 - Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma	26/07/2017	Yes	
TA461 - Roflumilast for treating chronic obstructive pulmonary disease	26/07/2017	Yes	
TA460 - Adalimumab and dexamethasone for treating non-infectious uveitis	26/07/2017	Yes	
TA459 - Collagenase clostridium histolyticum for treating Dupuytren's contracture	26/07/2019	Yes	
TA458 - Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane	19/07/2017	Yes	
TA457 - Carfilzomib for previously treated multiple myeloma	19/07/2017	Yes	
TA456 - Ustekinumab for moderately to severely active Crohn's disease after previous treatment	12/07/2017	Yes	
TA455 - Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people	12/07/2017	Yes	
TA454 - Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma	05/07/2017	No	Appraisal terminated
TA453 - Bortezomib for treating multiple myeloma after second or subsequent relapse	05/07/2017	No	Appraisal terminated
TA452 - Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation	05/07/2017	No	Appraisal terminated
TA451 - Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia	28/06/2017	Yes	
TA450 - Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia	28/06/2017	No	Not applicable to CWFT
TA449 - Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease	28/06/2017	No	Not applicable to CWFT
TA448 - Etelcalcetide for treating secondary hyperparathyroidism	28/06/2017	No	Not applicable to CWFT
TA447 - Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer	28/06/2017	Yes	
TA446 - Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma	28/06/2017	Yes	

TA445 - Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs	24/05/2017	Yes	
TA444 - Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy	24/05/2017	No	Appraisal terminated
TA443 - Obeticholic acid for treating primary biliary cholangitis	26/04/2017	No	Not applicable to CWFT
TA442 - Ixekizumab for treating moderate to severe plaque psoriasis	26/04/2017	Yes	
TA441 - Daclizumab for treating relapsing–remitting multiple sclerosis	26/04/2017	Yes	
TA440 - Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabin	26/04/2017	No	Not applicable to CWFT